However, the FOXP3+ subset displayed significantly higher pSTAT5 levels relative to Tcon cells in patients treated with CIT than in patients treated with ibrutinib, untreated CLL patients with advanced disease, or HCs (Figure 5H). This evidence concerns the gene FOXP3 and B-cell chronic lymphocytic leukemia.